Metagenomi Therapeutics (MGX) EBT Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly EBT Margin of 1846.88% for Q1 2026, down 124254.0% year-over-year from N/an in Q1 2025, and down 221.11% quarter-over-quarter from 575.15% in Q4 2025.
Metagenomi Therapeutics (MGX) EBT Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported EBT Margin for 4 consecutive years, with 1846.88% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 124254.0% year-over-year to 1846.88%; the TTM figure through Mar 2026 stood at 385.27% (down 20109.0% YoY), while the FY2025 annual figure was 348.77%, down 18897.0% from the prior year.
- EBT Margin declined to 1846.88% in Q1 2026 per MGX's latest filing, from 575.15% in the prior quarter.
- Across five years, EBT Margin topped out at 64.66% in Q2 2024 and bottomed at 1846.88% in Q1 2026.
- Historically, EBT Margin has averaged 366.8% across 4 years, with a median of 225.36% in 2024.
- Annual changes were most pronounced in 2024 — EBT Margin surged 3333 bps — and 2026, when it sank 124254 bps.
- Metagenomi Therapeutics' EBT Margin stood at 133.62% in 2023, then slumped by 92 bps to 255.94% in 2024, then sank by 125 bps to 575.15% in 2025, then sank by 221 bps to 1846.88% in 2026.
- Business Quant data shows MGX's EBT Margin at 1846.88% in Q1 2026, 575.15% in Q4 2025, and 238.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,846.88% |
| Dec 31, 2025 | -575.15% |
| Sep 30, 2025 | -238.21% |
| Jun 30, 2025 | -233.34% |
| Mar 31, 2025 | -604.34% |
| Dec 31, 2024 | -255.94% |
| Sep 30, 2024 | -181.34% |
| Jun 30, 2024 | -64.66% |
| Mar 31, 2024 | -225.36% |
| Dec 31, 2023 | -133.62% |
| Sep 30, 2023 | -150.56% |
| Jun 30, 2023 | -98.00% |
| Mar 31, 2023 | -160.98% |